Abstract

You have accessJournal of UrologyPenis/Testis/Urethra: Benign & Malignant Disease III1 Apr 2012919 LYMPHANGIOGENESIS IN NON SEMINOMATOUS TESTICULAR CANCER AND ITS ASSOCIATION TO THE STATUS OF METASTASIS AT DIAGNOSIS Julia Heinzelbecker, Tobias Gropp, Christel Weiß, Katrin Hüttl, Annette Steidler, Axel Haecker, Christian Bolenz, and Lutz Trojan Julia HeinzelbeckerJulia Heinzelbecker Mannheim, Germany More articles by this author , Tobias GroppTobias Gropp Mannheim, Germany More articles by this author , Christel WeißChristel Weiß Mannheim, Germany More articles by this author , Katrin HüttlKatrin Hüttl Mannheim, Germany More articles by this author , Annette SteidlerAnnette Steidler Mannheim, Germany More articles by this author , Axel HaeckerAxel Haecker Mannheim, Germany More articles by this author , Christian BolenzChristian Bolenz Mannheim, Germany More articles by this author , and Lutz TrojanLutz Trojan Mannheim, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1016AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To evaluate the role of lymph vessel density (LVD) and lymphangiogenesis in nonseminomatous testicular germ cell tumors (NSGCT) using the specific lymphatic endothelial cell (LEC) marker LYVE-1. METHODS Paraffin embedded tumor samples from 77 patients (clinical stage 1: n=45; metastatic disease: n=32) were stained with the LEC marker LYVE-1. LVD was assessed in different areas using a standardised method. Proliferating LECs were detected using fluorescence double immunostaining of LYVE-1 and Ki67 in a subgroup of 50 patients. The presence of lymphatic vascular invasion (LVI) was documented. The parameters were correlated with clinico-pathological data. Median follow-up was 46 (range: 3 – 170) months. RESULTS Peritumoral lymph vessels were identified in 57 patients (74.0%; mean LVD: 2.16 (±2.17)), intratumoral lymph vessels in 11 patients (14.3%; mean LVD: 0.16 (± 0.73)) and nontumoral lymph vesssels in 56 patients (81.2%; mean LVD: 3.17 (±3.24)). Higher peritumoral LVD was associated with the presence of metastatic disease at diagnosis (p= 0.0824). In five patients (10%) proliferating lymphatic vessels were present. Four of these patients had metastatic disease at diagnosis. None of these patients relapsed nor died. Altogether four patients relapsed and four patients died one of them due to relapse of the disease. In three of the four patients who died peritumoral lymph vessels were present with a mean LVD of 3.88 (± 2.99). Lymphvascular invasion was found in 24 patients (31.2%). The presence of LVI was significantly associated with metastatic disease at the time of diagnosis (p= 0.0121). LVI was significantly more frequent in tumours with a high peritumoral LVD (p= 0.0005). CONCLUSIONS For the first time we evaluated LVD in NSGCT. Our findings show an association of LVD with metastatic disease at diagnosis. The existence of proliferating lymphatic vessels indicates that lymphangiogenesis may play a role in the dissemination of NSGCT. LVI was associated with metastasis at the time of diagnosis. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e374-e375 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Julia Heinzelbecker Mannheim, Germany More articles by this author Tobias Gropp Mannheim, Germany More articles by this author Christel Weiß Mannheim, Germany More articles by this author Katrin Hüttl Mannheim, Germany More articles by this author Annette Steidler Mannheim, Germany More articles by this author Axel Haecker Mannheim, Germany More articles by this author Christian Bolenz Mannheim, Germany More articles by this author Lutz Trojan Mannheim, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call